Researchers identified a novel bladder cancer (BCa) prognostic scoring signature that may be useful for BCa immunotherapies. The findings were published in BMC Cancer.
This retrospective study included muscle-invasive BCa (MIBC) patients who underwent radical cystectomy in Shanghai General Hospital from 2007 to 2018. The investigators analyzed 13 immune-related differential expression proteins and their associated genes. They used an immune-related prognostic signature (IRPS) to assess the feasibility of gene sequencing. The study included 1010 BCa patients partitioned according to dataset: 405 BCa patients in the Cancer Genome Atlas cohort, 476 BCa patients in the ArrayExpress cohort, and 129 MIBC patients in the Shanghai General Hospital cohort.
According to the results, the IRPS score was associated with a poor overall 5-year survival rate and disease-free survival. The researchers observed that higher IRPS scores correlated with more M2 macrophage and increased resting mast cell infiltration.
Reference: Jiang L, Chen S, Pan Q, et al. The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients. BMC Cancer. 2022;22(1):676. doi:10.1186/s12885-022-09783-y
